CN1061035C - 苯基链烷醇胺衍生物及其制备方法和用途 - Google Patents

苯基链烷醇胺衍生物及其制备方法和用途 Download PDF

Info

Publication number
CN1061035C
CN1061035C CN94115651A CN94115651A CN1061035C CN 1061035 C CN1061035 C CN 1061035C CN 94115651 A CN94115651 A CN 94115651A CN 94115651 A CN94115651 A CN 94115651A CN 1061035 C CN1061035 C CN 1061035C
Authority
CN
China
Prior art keywords
compound
methyl
phenyl
formula
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN94115651A
Other languages
English (en)
Chinese (zh)
Other versions
CN1105990A (zh
Inventor
E·莫哈西
J·P·奥布赖恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1105990A publication Critical patent/CN1105990A/zh
Application granted granted Critical
Publication of CN1061035C publication Critical patent/CN1061035C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
  • Organic Insulating Materials (AREA)
  • Table Devices Or Equipment (AREA)
  • Fats And Perfumes (AREA)
  • Indole Compounds (AREA)
CN94115651A 1993-09-02 1994-09-01 苯基链烷醇胺衍生物及其制备方法和用途 Expired - Fee Related CN1061035C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11638593A 1993-09-02 1993-09-02
US116,385 1993-09-02

Publications (2)

Publication Number Publication Date
CN1105990A CN1105990A (zh) 1995-08-02
CN1061035C true CN1061035C (zh) 2001-01-24

Family

ID=22366865

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94115651A Expired - Fee Related CN1061035C (zh) 1993-09-02 1994-09-01 苯基链烷醇胺衍生物及其制备方法和用途

Country Status (22)

Country Link
EP (1) EP0648744B1 (enExample)
JP (1) JP2610784B2 (enExample)
KR (1) KR100360954B1 (enExample)
CN (1) CN1061035C (enExample)
AT (1) ATE162520T1 (enExample)
AU (1) AU7149794A (enExample)
BR (1) BR9403418A (enExample)
CA (1) CA2129771C (enExample)
CZ (1) CZ210694A3 (enExample)
DE (1) DE69408078T2 (enExample)
DK (1) DK0648744T3 (enExample)
ES (1) ES2113585T3 (enExample)
FI (1) FI107607B (enExample)
GR (1) GR3026622T3 (enExample)
HU (1) HUT70558A (enExample)
IL (1) IL110812A0 (enExample)
NO (1) NO943231L (enExample)
NZ (1) NZ264320A (enExample)
PL (1) PL304863A1 (enExample)
RU (1) RU94031753A (enExample)
TW (1) TW281670B (enExample)
ZA (1) ZA946529B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658909A (en) * 1994-11-17 1997-08-19 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease
US5693804A (en) * 1994-11-17 1997-12-02 Molecular Geriatrics Corporation Substituted 1-aryl-3-piperazin-1'-yl propanones
US6214994B1 (en) 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
FR2742051B1 (fr) * 1995-12-06 1998-02-06 Synthelabo Utilisation de composes ayant une affinite pour le site de liaison du (3h)ifenprodil pour la fabrication de medicaments utiles dans la prevention et le traitement des neuropathies
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610736B (en) * 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
PL340080A1 (en) 1997-10-24 2001-01-15 Warner Lambert Co Method of treating disease-related or post-drug dyskinesias
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
DE19812331A1 (de) * 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
DE60228969D1 (enExample) * 2001-07-24 2008-10-30 Richter Gedeon Nyrt
WO2005030720A1 (ja) 2003-09-25 2005-04-07 Shionogi & Co., Ltd. Ｎｍｄａ受容体拮抗作用を有するピペリジン誘導体
MX2014004469A (es) 2011-11-22 2014-08-01 Univ California Metodos y composiciones para tratar inflamacion y lesion isquemica.
RU2649406C1 (ru) * 2017-09-21 2018-04-03 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 3-n-замещенные борнилпропионаты, используемые в качестве ингибиторов вируса марбург

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4261285A (en) * 1984-06-01 1985-12-05 Tokyo Tanabe Company Limited 1-propanone derivatives
DE3433036A1 (de) * 1984-09-08 1986-03-20 Basf Ag, 6700 Ludwigshafen Piperidinderivate und diese enthaltende fungizide sowie verfahren zur bekaempfung von pilzen
EP0398578B1 (en) * 1989-05-17 1997-03-12 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
US4940789A (en) * 1989-10-10 1990-07-10 American Home Products Corporation 10,11-dihydro-5-alkyl-12-substituted-10,5-(iminomethano)-5H-dibenzo[a,d]cycloheptenes as neuroprotectant agents
EP0553278B1 (en) * 1990-10-15 1997-06-04 Astra Aktiebolag 2-phenyl-and 2-thienyl-(2)-piperidine derivatives having neuroprotective properties
SE9003652D0 (sv) * 1990-11-15 1990-11-15 Astra Ab New heterocyclic compounds

Also Published As

Publication number Publication date
KR100360954B1 (ko) 2003-04-16
NZ264320A (en) 1996-02-27
NO943231L (no) 1995-03-03
ATE162520T1 (de) 1998-02-15
AU7149794A (en) 1995-03-16
RU94031753A (ru) 1996-07-20
DK0648744T3 (da) 1998-09-21
HUT70558A (en) 1995-10-30
FI944044A0 (fi) 1994-09-02
EP0648744A1 (en) 1995-04-19
ES2113585T3 (es) 1998-05-01
PL304863A1 (en) 1995-03-06
NO943231D0 (no) 1994-09-01
ZA946529B (en) 1995-03-02
EP0648744B1 (en) 1998-01-21
KR950008481A (ko) 1995-04-17
BR9403418A (pt) 1996-09-03
JPH0782250A (ja) 1995-03-28
DE69408078T2 (de) 1998-07-09
FI107607B (fi) 2001-09-14
GR3026622T3 (en) 1998-07-31
FI944044L (fi) 1995-03-03
HU9402479D0 (en) 1994-10-28
CZ210694A3 (en) 1995-08-16
IL110812A0 (en) 1994-11-11
JP2610784B2 (ja) 1997-05-14
CN1105990A (zh) 1995-08-02
CA2129771C (en) 2006-03-21
DE69408078D1 (de) 1998-02-26
CA2129771A1 (en) 1995-03-03
TW281670B (enExample) 1996-07-21

Similar Documents

Publication Publication Date Title
CN1061035C (zh) 苯基链烷醇胺衍生物及其制备方法和用途
CN1037439C (zh) 制备具有神经保护作用的吲哚酮及有关衍生物的方法
CN1285578C (zh) 取代苯甲酸酰胺及其在抑制血管生成中的应用
CN1065536C (zh) 2－甲基－噻吩并苯并二氮杂䓬的结晶形式及制备方法
CN1028104C (zh) 制备喹诺酮衍生物的方法
CN1034552C (zh) 十氢异喹啉衍生物的药物制剂的制备方法
CN1029960C (zh) 具有神经保护作用的苯并二氢吡喃醇衍生物的制备方法
CN1093363A (zh) 取代的吡唑
CN1124960A (zh) 作为5-ht/a和/或5-ht2配体的吲哚衍生物
CN86107627A (zh) 新颖的4-苄基-1-(2h)-酞嗪酮衍生物的制备方法
CN1703404A (zh) 制备10,11－二氢－10－羟基－5H－二苯并(b,f)氮杂䓬－5－甲酰胺的两种对映异构体的对映选择性方法及其新晶形
CN1128026A (zh) 新型1，4-(二苯基烷基)哌嗪衍生物
CN1678614A (zh) N－甲基－N(3－{3－[2－噻吩基羰基]－吡唑－[1,5－α]－嘧啶－7－基}苯基)乙酰胺的新型多形体及其相关组合物和方法
CN1152919A (zh) 三唑化合物、及其作为多巴胺d3配位体的应用
CN1039491C (zh) 四氢咔唑化合物及其制备方法和应用
CN1217720A (zh) 苯并呋喃基衍生物及其应用
CN1109471A (zh) 咪唑-4-基哌啶衍生物及其制备方法和在治疗中的应用
CN1016246B (zh) 氨基酚衍生物的制备方法
CN1330069A (zh) 新的取代的2－苯并[c]呋喃酮化合物,其制备方法以及包含它们的药物组合物
CN1035114A (zh) 四唑刺激性氨基酸受体拮抗药
CN101039910A (zh) 适合制备药物组合物的多奈哌齐盐
CN1097006A (zh) O-芳基吗啡喃的醚类化合物
CN1293195A (zh) 新的多环氮杂吲哚化合物,其制备方法及包含它们的药物组合物
CN1069491A (zh) 2-(哌啶-1-基)乙醇衍生物，其制法及其治疗应用
CN1414962A (zh) 用于治疗中枢神经系统疾病的[(吲哚－3－基)－环烷基]－3－取代的氮杂环丁烷

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee